Lysine-specific histone demethylase 1A (LSD1) in cervical cancer
- PDF / 1,135,056 Bytes
- 8 Pages / 595.276 x 790.866 pts Page_size
- 19 Downloads / 170 Views
ORIGINAL ARTICLE – CANCER RESEARCH
Lysine‑specific histone demethylase 1A (LSD1) in cervical cancer Daniel Beilner1 · Christina Kuhn1 · Bernd P. Kost1 · Julia Jückstock1 · Doris Mayr2 · Elisa Schmoeckel2 · Christian Dannecker3 · Sven Mahner1 · Udo Jeschke1,3 · Helene Hildegard Heidegger1 Received: 3 May 2020 / Accepted: 23 July 2020 © The Author(s) 2020
Abstract Purpose Demethylation of DNA through enzymes like LSD1 showed a crucial impact on different kind of cancers. Epigenetic modifications in cervical cancer are still not fully investigated nevertheless of high interest for a therapeutic use. Methods Tumor samples of 250 cervical cancer patients were immunochemically stained and evaluated based on Immunoreactive Score. Results were statistically analyzed for clinical and pathological parameters. Results Our patient collective showed a disadvantage for 10-year survival for patients with a strong expression of LSD1 in the cytoplasm of cervical cancer cells. The results of the correlational analysis further revealed a negative correlation of LSD1 to G-protein coupled estrogen receptor (GPER). Conclusions Epigenetic changes through enzymes like LSD1 may also be of interest for patients with cervical cancer. A combined therapy with other proteins relayed to cervical cancer like GPER might be of interest for future investigations. Keywords LSD1 · Epigenetic modification · DNA methylation · GPER · Cervical cancer · Survival
Background Cervical cancer is with about 570,000 new cases in the year 2018, the fourth most frequent cancer after breast, colorectum and lung carcinoma in women worldwide. It represents about 6.6% of all female cancers. About 311,000 deaths occurred in 2018 caused of cervical cancer (World Health Organization [WHO (2020a)].About 90% of the cervical cancer deaths occur in low and middle- income countries. Prevention, early diagnosis, effective screening and treatment programmes are essential to reduce the mortality rate of cervical cancer (World Health Organization [WHO (2020b)]. The two main histologic subtypes are squamous cell carcinoma with about 80% and adenocarcinoma with about 20% (Aviel-Ronen et al. 2016).
* Udo Jeschke [email protected]‑muenchen.de 1
Department of Obstetrics and Gynaecology, LMU Munich, Marchioninistraße 15, 81377 Munich, Germany
2
Department of Pathology, LMU Munich, Thalkirchner Str. 56, 80337 Munich, Germany
3
Department of Obstetrics and Gynaecology, University Hospital Augsburg, Stenglinstr. 2, 86156 Augsburg, Germany
Cervical cancer is usually caused by persistent high-risk Human Papillomavirus (HR-HPV) infection, with human papillomavirus (HPV) being the most common sexually transmitted biological agent. About 85% of anogenital cancers in men and women are related to HPV infection (Leite et al. 2020). HPV belongs to the Papillomaviridae family and is a circular, non-enveloped double-stranded DNA virus. Many subtypes have already been identified (Leite et al. 2020; Goodman 2015). There is a sub-classification of HPV infections of the genit
Data Loading...
